Discovery of VU0467319: an M1 Positive Allosteric Modulator Candidate That Advanced into Clinical Trials
{{output}}
Herein we detail the first disclosure of VU0467319 (VU319), an M1 Positive Allosteric Modulator (PAM) clinical candidate that successfully completed a Phase I Single Ascending Dose (SAD) clinical trial. VU319 (16) is a moderately potent M1 PAM (M1 PAM EC50 = 4... ...
